|
Use Device Component in Combo Product Trials, Produce Drug-Level Data
Drugmakers should include the device component of a combination product in the pivotal trial of the drug or biologic or face additional regulatory hurdles later, a top FDA official said.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives